Literature DB >> 12923892

Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats.

Mitsuori Mayahara1, Takahisa Sasaki.   

Abstract

We examined the effects of long-term bisphosphonate (BP, pamidronate) administration at a therapeutic dose (1.5 mg/kg/day) on the distribution, structure, and vacuolar-type H(+)-ATPase expression of osteoclasts, and the resulting trabecular bone volume and structure in ovariectomized (OVX) mature rats. Six-month-old female rats were allocated to sham-operated control, untreated-OVX, and BP-administered OVX groups. Postoperatively, BP was administered intraperitoneally once a day to OVX rats for up to 30 days. On postoperative days 14, 30, and 60, all of the rats were killed and the distal metaphyseal area of the dissected humeri was examined. Quantitative backscattered-electron image analysis revealed that the trabecular bone volume/unit medullary area in untreated OVX rats was significantly (P < 0.05) lower than that in sham-operated controls at 30 and 60 days postoperation. BP administration significantly (P < 0.05) increased trabecular bone volume at 14, 30, and 60 days postoperation in BP-administered OVX rats compared to both sham-operated and untreated OVX rats. Compared to untreated OVX rats, the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts along the bone trabeculae in BP-administered OVX rats was not significantly decreased on days 14 and 30, but was significantly decreased on day 60. Ultrastructurally, BP administration caused the disappearance of both the ruffled border (RB) and the clear zone (CZ) structures, and decreased the expression of vacuolar-type H(+)-ATPase in most osteoclasts, but did not significantly induce apoptosis of osteoclasts detected by the terminal dUTP nick end-labeling (TUNEL) method. Our results suggest that long-term BP administration significantly reduces bone and calcified cartilage resorption through impairment of the structure and bone-resorbing function of osteoclasts, and thereby effectively maintains trabecular bone volume and structure in ovariectomy-induced acute estrogen deficiency in mature rats. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923892     DOI: 10.1002/ar.a.10092

Source DB:  PubMed          Journal:  Anat Rec A Discov Mol Cell Evol Biol        ISSN: 1552-4884


  3 in total

1.  Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice.

Authors:  Hongrui Liu; Jian Cui; Jing Sun; Juan Du; Wei Feng; Bao Sun; Juan Li; Xiuchun Han; Bo Liu; Kimimitsu Oda; Norio Amizuka; Minqi Li
Journal:  J Mol Histol       Date:  2015-05-13       Impact factor: 2.611

2.  Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC.

Authors:  Sang Shin Lee; Soung Min Kim; Yeon Sook Kim; Suk Keun Lee
Journal:  PeerJ       Date:  2020-05-21       Impact factor: 2.984

3.  Pamidronate Down-regulates Tumor Necrosis Factor-alpha Induced Matrix Metalloproteinases Expression in Human Intervertebral Disc Cells.

Authors:  Young-Mi Kang; Seong-Hwan Hong; Jae-Ho Yang; Jin-Cheol Oh; Jin-Oh Park; Byung Ho Lee; Sang-Yoon Lee; Hak-Sun Kim; Hwan-Mo Lee; Seong-Hwan Moon
Journal:  J Bone Metab       Date:  2016-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.